Methods of improving the pharmacokinetics of doxepin

Details Methods of improving the pharmacokinetics of doxepin Methods of improving the pharmacokinetics of doxepin

2011-03-29

2011-03-29

Landau, Sharmila Gollamudi (Department: 1611)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S923000

Reexamination Certificate

active

07915307

ABSTRACT:
Methods of improving the pharmacokinetics of doxepin in a patient.

REFERENCES:
patent: 3420851 (1969-01-01), Bloom et al.
patent: 3438981 (1969-04-01), Stach
patent: 3509175 (1970-04-01), Tretter
patent: 4110438 (1978-08-01), Gahwyler
patent: 4434171 (1984-02-01), Muller
patent: 5030632 (1991-07-01), Sterling
patent: 5116852 (1992-05-01), Gammans
patent: 5332661 (1994-07-01), Adamczyk et al.
patent: 5502047 (1996-03-01), Kavey
patent: 5502047 (1996-03-01), Kavey
patent: 5643897 (1997-07-01), Kavey
patent: 6211229 (2001-04-01), Kavey
patent: 6219674 (2001-04-01), Classen
patent: 6344487 (2002-02-01), Kavey
patent: 6407128 (2002-06-01), Scaife et al.
patent: 6584472 (2003-06-01), Classen
patent: 6683102 (2004-01-01), Scaife et al.
patent: 7135196 (2006-11-01), Stockham
patent: 7276536 (2007-10-01), Urata et al.
patent: 7452872 (2008-11-01), Johnson
patent: 2002/0037828 (2002-03-01), Wilson et al.
patent: 2002/0197235 (2002-12-01), Moran
patent: 2003/0235617 (2003-12-01), Martino et al.
patent: 2005/0123609 (2005-06-01), Hirsh et al.
patent: 2005/0239838 (2005-10-01), Edgar et al.
patent: WO 99/40898 (1999-08-01), None
http://apma-nc.com/PatientEducation/INSOMNIA.HTM, 2000, 1-4.
Prescription Drugs, http://www.grandtimes.com/Answer—Drugs.html, 1999, 1-3.
Adapin, http://www.depression-guide.com/adapin.htm, 2005, 1-3.
Somaxon's SILENOR™ Demonstrates Positive Results in Long-Term Phase 3 Clinical Trial in Elderly Patients with Insomnia, Somaxon Pharmaceuticals, p. 1-7, (Dec. 18, 2006).
Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-dose Doxepin in Adults with Primary Sleep Maintenance Insomnia, Somaxon Pharmaceuticals, p. 1-2, (Jan. 6, 2005).
Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Elderly Patients with Primary Sleep Maintenance Insomnia, Somaxon Pharmaceuticals, p. 1-3, (Apr. 21, 2005).
Somaxon Pharmaceuticals Announces Positive Phase 3 Results with SILENOR™ for the Treatment of Adults with Chronic Insomnia, Somaxon Pharmaceuticals, p. 1-5, (Apr. 10, 2006).
Somaxon Pharmaceuticals' SILENOR™ Demonstrates Positive Results in a Phase 3 Transient Insomnia Clinical Trial, Somaxon Pharmaceuticals, p. 1-5, (Oct. 23, 2006).
Somaxon Pharmaceuticals' SILENOR™ Demonstrates Positive Results in its Third Phase 3 Clinical Trial in Insomnia, Somaxon Pharmaceuticals, p. 1-6, (Nov. 20, 2006).
Shu et al.,Drug Metabolism&Disposition, 18: 735-741, (1990).
Luo et al.,Drug Metabolism&Disposition, 19:722-724, (1991).
Hobbs,Biochem. Pharmacol., 18: 1941-1954, (1969).
Moody et al.,Drug Metabolism&Disposition, 27: 1157-1164, (1999).
Denchle et al.,Psychopharmacology, 131: 19-22, (1997).
Shu et al.,Drug Metabolism&Disposition, 18: 1096-1099 (1990).
Grundstrom et al.,Sedative Properties of Doxepin in Comparison with Diazepam, Psychopharmacology, 54: 165-169 (1977).
Richelson,Tricyclic Antidepressants and Histamine H1 Receptors, Mayo Clin Proc., 54:669-674, (1979).
Physicians Desk Reference, Litton Industries, p. 1211, 93, (1976).
Vincent et al.,Use of Human Sleep as a Test of Drug's Psychotropic Action with Doxepin as an example, Bordeaux Medical, No. 10, 2650-51, 2653-54, 2657-57, and 2661, (1971).
Zung,Effect of Antidepressant Drugs on Sleeping and Dreaming, Excerpta Medica Foundation International Congress Series, No. 150, 1824-1826, (1968).
Ware,Tricyclic Antidepressants in the Treatment of Insomnia, Journal of Clinical Psychiatry, 44 [9, Section 2]: 25-28 (1983).
Technical Information/Summary of Drug Characteristics (SPC), Pfizer, p. 1-4, (2004).
Physicians' Desk Reference, p. 2434-2435, (1990).
Physicians' Desk Reference, p. 1849-1850, (1990).
Physicians' Desk Reference, p. 1310-1312, (1990).
Pecknold et al.,Trimipramine, Anxiety, Depression and Sleep, Drugs, vol. 38: Suppl. 1, p. 25-31, (1989).
Patent Information Leaflet, Sinequan™ (doxepin), United Kingdom, p. 1-2 (2002).
Nierenberg et al.,Management of Monoamine Oxidase Inhibitor-Associated Insomnia with Trazodone, Journal of Clinical Psychopharmacol, vol. 9 No. 1, p. 42-45, (1989).
Nicholson et al.,Modulation of sleep by trimipramine in man, European Journal of Clinical Pharmacol, 37: 145-150, (1989).
Kales et al.,Effects of Sinequan on sleep of Insomniac Subjects, Sleep Study Abstracts, p. 93, (1972).
Hartmann et al.,The Effects of Long Term Administration of Psychotropic Drugs on Human Sleep: Ill. The Effects of Amitriptyline, Psychopharmacologia, 33: 185-202 (1973).
Jacobsen,Low-Dose Trazodone as a Hypnotic in Patients Treated with MAOIs and Other Psychotropics: A Pilot Study, Journal of Clinical Psychiatry, 51: 298-392 (1990).
Gillin et al.,Successful Separation of Depressed, Normal, and Insomniac Subjects by EEG Sleep Data, Arch Gen Psychiatry, vol. 36, p. 85-90, (1979).
German Federal Gazette (BAnz) No. 240 of Dec. 22, 1992, p. 9545 (vol. 44).
Dunleavy et al.,Changes During Weeks in Effects of Tricyclic Drugs on the Human Sleeping Brain, British Journal of Psychiatry, 120: 663-672, (1972).
Conn et al.,Pattern of Use of Antidepressants in Long-Tem Care Facilities for the Elderly, Journal of Geriatric Psychiatry and Neurology, vol. 5:4, p. 228-232, (1992).
ABPI (Association of the British Pharmaceutical Industry) Medicines Compendium, 2002; Pfizer Limited, p. 1792-1793.
ABPI (Association of the British Pharmaceutical Industry) Compendium of Data Sheets & SmPC's, 1999-2000; Pfizer Limited, p. 1158-1159.
ABPI (Association of the British Pharmaceutical Industry) Compendium of Data Sheets and Summaries of Product Characteristics, 1996-1997; Pfizer Limited, p. 751-752.
ABPI (Association of the British Pharmaceutical Industry) Data Sheet Compendium 1995-1996; Pfizer Limited, p. 1239-1240.
ABPI (Association of the British Pharmaceutical Industry) Data Sheet Compendium 1994-1995; Pfizer Limited, p. 1150-1151.
ABPI (Association of the British Pharmaceutical Industry) Data Sheet Compendium 1993-1994; Pfizer Limited, p. 1205-1207.
ABPI (Association of the British Pharmaceutical Industry) Data Sheet Compendium 1991-1992; Pfizer Limited, p. 1147-1149.
Chen,Sleep, Depression and Antidepressants, British Journal of Psychiatry, 135: 385-402, (1979).
Hajak et al.,Nocturnal Melatonin Secretion and Sleep after Doxepin Administration in Chronic Primary Insomnia, Pharmacopsychiatry 29: 187-192, (1996).
National Academy of Sciences,Sleeping Pills, Insomnia, and Medical Practice, Institute of Medicine, 32-33,103,125,149,169,198, (1979).
Schatzberg et al., “Hypnotics” Manual of Clinical Psychopharmacology, American Psychiatric Press, Inc., Washington D.C., p. 173-189, (1986).
Seminar on Psychosomatics,Auspices ofAcademy of Psychosomatic Medicine, p. 4-63 (1968).
Pfizer,Chemist Review of NNA 17-516, Division of Neurophamacological Drug Products, Chemists Review#3, (1973).
Summary Basis for approval of ADAPIN (1972) Pursuant to FOIA Request filed in 1981.
Roth et al.,Psychopharmacolodgy: The Effects of Doxepin HCI on Sleep and Depression, Journal of Clinical Psychiatry, 43:9, p. 366-368 (1982).
Lapp,Chronic Fatigue Syndrome is a Real Disease, North Carolina Family Physician, 43:1, (1992).
Roth et al.,Efficacy and Safety of doxepin 1, 3 , and 6mg in elderly adults with primary insomnia, Sleep (Rochester),29: suppl. S (2006).
Hsu et al.,Low-Dose Doxepin in the treatment of primary insomnia, Sleep, 28: suppl, p. A50, (2005).
Doxal. Lääkeopas. Retrieved Nov. 28, 2005 from http://www.coronaria.fi/www/mtv3/laakkeet.php?id=299.
Doxal. Lääkkeet. Retrieved Nov. 28, 2005 from http:www.tohtori.fi/laakkeet/tuote.php3?ID=412.
Pharmaca Fennica. Published by the Finnish Centre for Medicine Information (Lääketietokeskus); Ye R Doxal; 534-535 (2000).
Pharmaca Fennica. Published by the Finnish Centre for Medicine Information (Lääketietokeskus); SR Doxal; 830 (1995).
Pharmaca Fennica. Published by the Finnish Centre for Medicine Information (Lääketietokeskus); SR Doxal; (1992).
Pharmaca Fennica. Published by the Finnish Centre for Medicine Information

Affiliated with

Also associated with

Rating

Methods of improving the pharmacokinetics of doxepin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of improving the pharmacokinetics of doxepin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of improving the pharmacokinetics of doxepin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2647639